Shorter vs standard venetoclax with azacitidine for older AML patients
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares a shorter course (7 days) of the targeted drug venetoclax with the standard longer course, both given along with the chemotherapy drug azacitidine. It is for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot tolerate intensive chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 60 or older
- Newly diagnosed AML (no prior treatment for AML or MDS)
- Considered unable to have standard intensive chemotherapy because of age or other health problems
- Adequate kidney and liver function (your doctor will check)
- No specific genetic types of AML (like favorable chromosome changes) or APL (a rare subtype)
- Willing to undergo bone marrow biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a shorter course of venetoclax, based on early bone marrow results, works as well as the standard longer course. It is for older adults or younger patients with health issues that make standard intensive chemo too risky.
This study tests whether a shorter or longer course of the drug venetoclax works better for older adults with a type of blood cancer called acute myeloid leukemia (AML) who are not healthy enough for intensive chemotherapy. The goal is to find the best treatment duration to control the cancer while reducing side effects.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.